Steven Pieper - Xeris Pharmaceuticals Chief Officer
| XERS Stock | USD 3.20 0.02 0.62% |
Insider
Steven Pieper is Chief Officer of Xeris Pharmaceuticals
| Age | 48 |
| Address | 180 North LaSalle Street, Chicago, IL, United States, 60601 |
| Phone | 844 445 5704 |
| Web | https://www.xerispharma.com |
Steven Pieper Latest Insider Activity
Tracking and analyzing the buying and selling activities of Steven Pieper against Xeris Pharmaceuticals stock is an integral part of due diligence when investing in Xeris Pharmaceuticals. Steven Pieper insider activity provides valuable insight into whether Xeris Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Xeris Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Xeris Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Steven Pieper over two months ago Disposition of 2640 shares by Steven Pieper of Xeris Pharmaceuticals at 1.55 subject to Rule 16b-3 | ||
Steven Pieper over three months ago Disposition of 14767 shares by Steven Pieper of Xeris Pharmaceuticals at 2.61 subject to Rule 16b-3 | ||
Steven Pieper over six months ago Acquisition by Steven Pieper of 25000 shares of Xeris Pharmaceuticals at 1.9967 subject to Rule 16b-3 | ||
Steven Pieper over six months ago Acquisition by Steven Pieper of 750000 shares of Xeris Pharmaceuticals subject to Rule 16b-3 |
Xeris Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.087) % which means that it has lost $0.087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.1716) %, meaning that it created substantial loss on money invested by shareholders. Xeris Pharmaceuticals' management efficiency ratios could be used to measure how well Xeris Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 8.67 in 2025, whereas Return On Tangible Assets are likely to drop (0.31) in 2025. At this time, Xeris Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 5.5 M in 2025, despite the fact that Net Tangible Assets are likely to grow to (84 M).Similar Executives
| Showing other executives | INSIDER Age | ||
| Sandeep MD | Immunitybio | N/A | |
| David Dornan | Elevation Oncology | 47 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Alexandra HughesWilson | Mereo BioPharma Group | 54 | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| MSc MBA | Inozyme Pharma | 53 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Barry MD | Immunitybio | 60 | |
| Klaus Orlinger | Hookipa Pharma | 47 | |
| Nathalie Riebel | PDS Biotechnology Corp | N/A | |
| James Balkovec | Cidara Therapeutics | N/A | |
| Christine MBA | Hookipa Pharma | 59 | |
| Fiona Bor | Mereo BioPharma Group | N/A | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Lauren MD | PDS Biotechnology Corp | 64 | |
| Valerie MD | Elevation Oncology | 47 | |
| Leonard MD | Immunitybio | N/A | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Joseph Ferra | Elevation Oncology | 50 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Ryan Bloomer | Elevation Oncology | N/A | |
Management Performance
| Return On Equity | -6.17 | ||||
| Return On Asset | -0.087 |
Xeris Pharmaceuticals Leadership Team
Elected by the shareholders, the Xeris Pharmaceuticals' board of directors comprises two types of representatives: Xeris Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xeris. The board's role is to monitor Xeris Pharmaceuticals' management team and ensure that shareholders' interests are well served. Xeris Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xeris Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD D, Senior Affairs | ||
| Beth JD, Chief Secretary | ||
| Steven Pieper, Chief Officer | ||
| Dr MBA, CoFounder Officer | ||
| Paul Edick, President CEO, Director | ||
| John Shannon, President COO | ||
| Paul JD, Senior Advisor | ||
| Kevin McCulloch, Chief Officer | ||
| Kendal Korte, Senior Resources | ||
| Brian Conner, SVP Officer | ||
| Allison Wey, Senior Communications |
Xeris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xeris Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.17 | ||||
| Return On Asset | -0.087 | ||||
| Profit Margin | (0.34) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 678.62 M | ||||
| Shares Outstanding | 149.08 M | ||||
| Shares Owned By Insiders | 3.92 % | ||||
| Shares Owned By Institutions | 43.99 % | ||||
| Number Of Shares Shorted | 10.19 M | ||||
| Price To Book | 3.34 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.